Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:approvalYear |
1998
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
J06BB16
|
| gptkbp:CASNumber |
170069-17-3
|
| gptkbp:chemicalFormula |
C6416H9910N1694O1987S46
|
| gptkbp:genericName |
gptkb:palivizumab
|
| gptkbp:halfLife |
20 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
Synagis
|
| gptkbp:indication |
high-risk infants and young children
|
| gptkbp:KEGGID |
D08347
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:AstraZeneca
|
| gptkbp:mechanismOfAction |
binds to RSV F protein
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:PubChem_CID |
1201582
DB00099 |
| gptkbp:routeOfAdministration |
intramuscular injection
|
| gptkbp:sideEffect |
fever
injection site reaction rash |
| gptkbp:target |
gptkb:RSV_fusion_protein
|
| gptkbp:type |
humanized monoclonal antibody
|
| gptkbp:UNII |
P0CW508T2I
|
| gptkbp:usedFor |
prevention of respiratory syncytial virus (RSV) infection
|
| gptkbp:bfsParent |
gptkb:MedImmune
|
| gptkbp:bfsLayer |
6
|